유전체학 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Genomics Market was valued at USD 44.7 billion in 2025 and is estimated to grow at a CAGR of 15.6% to reach USD 188.7 billion by 2035.

The genomics industry is witnessing substantial growth worldwide due to the increasing prevalence of chronic and inherited disorders, along with rising demand for precision-based healthcare solutions. Genomics focuses on the comprehensive analysis of genetic material to better understand biological functions, disease progression, and individualized therapeutic approaches. Continuous advancements in sequencing technologies, gene analysis platforms, artificial intelligence, and bioinformatics are accelerating the development of more accurate and efficient genomic applications across healthcare and life sciences. The growing integration of genomics into clinical diagnostics, therapeutic development, pharmaceutical research, and preventive healthcare is significantly transforming the industry landscape. In addition, the rising adoption of genomic technologies in disease identification, treatment optimization, and targeted medicine is supporting broader market expansion. Industry participants are actively strengthening their capabilities through technological innovation, expansion of genomic platforms, and strategic collaborations across biotechnology and healthcare ecosystems. Favorable regulatory support and improving reimbursement structures are also encouraging the wider implementation of genomics solutions across healthcare systems and research institutions globally.

The products segment accounted for 66.9% share in 2025 and is projected to reach USD 122.7 billion by 2035, growing at a CAGR of 15.3% 2026-2035. This segment primarily includes genomic instruments and consumable materials that are essential for conducting research activities and diagnostic procedures. Technological advancements in genomic equipment have significantly improved operational efficiency, scalability, and analytical accuracy, enabling greater adoption across research laboratories and clinical environments. Consumables continue to represent a critical portion of the segment due to their recurring use throughout genomic testing and laboratory workflows. Increasing demand for reliable genomic analysis and large-scale research capabilities is further driving growth within the products segment.

The sequencing segment generated USD 17 billion in 2025. Sequencing technologies continue to play a central role in market expansion as innovations improve processing speed, precision, and overall cost efficiency. Advanced sequencing platforms enable large-scale genetic analysis with enhanced accuracy and high-throughput capabilities, supporting wider application across research and clinical settings. The increasing use of sequencing technologies for comprehensive genomic evaluation and disease-related analysis is strengthening their importance across the healthcare and biotechnology industries. Ongoing technological progress and rising demand for efficient genomic interpretation are expected to sustain strong growth within the sequencing segment over the coming years.

North America Genomics Market held a 42.7% share in 2025. The region continues to maintain a leading position due to its advanced healthcare infrastructure, strong focus on biomedical research, and increasing implementation of genomics across clinical and scientific applications. Growing investments in precision healthcare initiatives, expanding biotechnology activities, and supportive research environments are contributing to regional market growth. Rising demand for personalized treatment approaches, early-stage disease identification, and advanced diagnostic technologies is also accelerating adoption throughout North America. The presence of major genomics innovators and continuous technological developments in sequencing, diagnostics, and bioinformatics are further enhancing accessibility and innovation across the regional market.

Key companies operating in the Global Genomics Market include Agilent Technologies, BGI Genomics, Bio-Rad Laboratories, Color Genomics, Danaher, Eppendorf, Eurofins Scientific, F. Hoffmann-La Roche, Illumina, Myriad Genetics, NVIDIA, Oxford Nanopore Technologies, Pacific Biosciences of California, QIAGEN, Quest Diagnostics, and Thermo Fisher Scientific. Companies operating in the Global Genomics Industry are adopting multiple strategic initiatives to strengthen their market position and expand their global presence. Leading players are heavily investing in research and development activities to introduce advanced sequencing systems, improved analytical software, and more efficient genomic testing solutions. Strategic partnerships with biotechnology firms, pharmaceutical companies, healthcare providers, and research organizations are helping companies accelerate innovation and broaden application areas. Market participants are also expanding their product portfolios through acquisitions and collaborations to enhance technological capabilities and improve service offerings. In addition, businesses are increasingly integrating artificial intelligence and data analytics into genomic platforms to improve data interpretation and operational efficiency. Several companies are focusing on geographic expansion, laboratory network development, and automation technologies to improve accessibility, streamline workflows, and strengthen long-term customer relationships across the global genomics market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Technology trends
  • 2.2.4 Application trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of genetic and chronic diseases
    • 3.2.1.2 Advancements in DNA sequencing and gene editing technologies
    • 3.2.1.3 Increasing adoption of precision medicine
    • 3.2.1.4 Government initiatives and funding for genomics research
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Ethical and privacy concerns around genetic data
    • 3.2.2.2 High cost and affordability issues
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of affordable and rapid sequencing technologies
    • 3.2.3.2 Integration of AI and machine learning for enhanced genomic data analysis
• 3.3 Growth potential analysis
• 3.4 Technology landscape
  • 3.4.1 Current technology
  • 3.4.2 Emerging technologies
• 3.5 Pricing Analysis (Driven by Primary Research)
• 3.6 Regulatory landscape (Driven by primary research)
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
  • 3.6.4 Latin America
  • 3.6.5 Middle East and Africa
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Impact of AI and generative AI on the market
• 3.10 Future market trends (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Products
  • 5.2.1 Instruments
  • 5.2.2 Consumables and reagents
• 5.3 Services
  • 5.3.1 NGS-based services
  • 5.3.2 Core genomics services
  • 5.3.3 Biomarker translation services
  • 5.3.4 Computational services
  • 5.3.5 Other services

Chapter 6 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 PCR (polymerase chain reaction)
• 6.3 Sequencing
• 6.4 Microarray
• 6.5 Nucleic acid extraction and purification
• 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Diagnostics
• 7.3 Drug discovery and development
• 7.4 Precision medicine
• 7.5 Agriculture and animal research
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Research centers and academic and government institutes
• 8.4 Pharmaceutical and biotechnology companies
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Agilent Technologies
• 10.2 BGI Genomics
• 10.3 Bio-Rad Laboratories
• 10.4 Color Genomics
• 10.5 Danaher
• 10.6 Eppendorf
• 10.7 Eurofins Scientific
• 10.8 F. Hoffmann-La Roche
• 10.9 Illumina
• 10.10 Myriad Genetics
• 10.11 NVIDIA
• 10.12 Oxford Nanopore Technologies
• 10.13 Pacific Biosciences of California
• 10.14 QIAGEN
• 10.15 Quest Diagnostics
• 10.16 Thermo Fisher Scientific